
    
      We are enrolling a patient who had successful conventional percutaneous coronary intervention
      after acute myocardial infarction. Patients are allocated to one of three groups
      (group1=comparator, group2= one dose of hearticellgram-AMI).

      single dose of hearticellgram-AMI have been attained new drug approval from MFDS (related to
      NCT01392105).
    
  